文献速递临床试验与 GCP

在低收入国家使用声门上气道装置进行新生儿复苏以改善死亡率和发病率结局:一项随机试验的研究方案

Neonatal resuscitation using a supraglottic airway device for improved mortality and morbidity outcomes in a low-income country: study protocol for a randomized trial.
PubMed 文献 · Trials · 2019-07-19

该研究为在乌干达Mulago医院开展的随机III期开放标签优效性对照试验,纳入胎龄大于34周、出生体重大于2000g且需正压通气的新生儿,比较声门上气道装置(i-gel®)与面罩通气对7日死亡率和新生儿脑病入住NICU复合结局的影响,计划样本量1150至1240例。

要点

  • 声门上气道装置(i-gel®)与面罩通气比较,主要结局为7日死亡率和新生儿脑病入住NICU的复合结局。
  • 纳入标准为胎龄大于34周、出生体重大于2000g且需正压通气的新生儿。
  • 计划样本量1150至1240例,按集群大小决定。

核心结论

  • 作者假设使用声门上气道装置比面罩更容易实现有效通气,从而降低早期新生儿死亡率和新生儿脑病导致的脑损伤。
  • 作者认为该试验结果对中低资源环境具有重要意义,因为大多数产时相关事件发生在这些地区。

研究设计与样本

  • 随机III期开放标签优效性对照临床试验,在乌干达坎帕拉Mulago医院的产房进行。
  • 干预前,实施复苏的卫生人员接受基于Helping Babies Breathe课程的培训,并包含声门上气道置入的专门模块。
  • 纳入需正压通气、预期胎龄大于34周且预期出生体重大于2000g的新生儿,计划样本量1150至1240例(取决于集群大小)。
  • 通过每日非盲随机化将新生儿分入声门上气道装置(i-gel®)组(干预组)或面罩组(对照组)。

主要发现

  • 乌干达的一项先导研究表明,助产士经过短期培训后可使用i-gel®安全复苏新生儿。
  • 目前尚无大型研究以死亡率和发病率为终点评估声门上气道装置在新生儿复苏中的效果。

关键数值与推荐

  • 主要结局为7日死亡率和因新生儿脑病入住新生儿重症监护病房(NICU)的复合结局。
  • 纳入标准:需正压通气、预期胎龄大于34周、预期出生体重大于2000g。
  • 试验注册:ClinicalTrials.gov,标识符NCT03133572,注册日期2017年4月28日。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intrapartum-related death is the third leading cause of under-5 mortality. Effective ventilation during neonatal resuscitation has the potential to reduce 40% of these deaths. Face-mask ventilation performed by midwives is globally the most common method of resuscitating neonates. It requires considerable operator skills and continuous training because of its complexity. The i-gel® is a cuffless supraglottic airway which is easy to insert and provides an efficient seal that prevents air leakage; it has the potential to enhance performance in neonatal resuscitation. A pilot study in Uganda demonstrated that midwives could safely resuscitate newborns with the i-gel® after a short training session. The aim of the present trial is to investigate whether the use of a cuffless supraglottic airway device compared with face-mask ventilation during neonatal resuscitation can reduce mortality and morbidity in asphyxiated neonates. METHODS: A randomized phase III open-label superiority controlled clinical trial will be conducted at Mulago Hospital, Kampala, Uganda, in asphyxiated neonates in the delivery units. Prior to the intervention, health staff performing resuscitation will receive training in accordance with the Helping Babies Breathe curriculum with a special module for training on supraglottic airway insertion. A total of 1150 to 1240 babies (depending on cluster size) that need positive pressure ventilation and that have an expected gestational age of more than 34 weeks and an expected birth weight of more than 2000 g will be ventilated by daily unmasked randomization with a supraglottic airway device (i-gel®) (intervention group) or with a face mask (control group). The primary outcome will be a composite outcome of 7-day mortality and admission to neonatal intensive care unit (NICU) with neonatal encephalopathy. DISCUSSION: Although indications for the beneficial effect of a supraglottic airway device in the context of neonatal resuscitation exist, so far no large studies powered to assess mortality and morbidity have been carried out. We hypothesize that effective ventilation will be easier to achieve with a supraglottic airway device than with a face mask, decreasing early neonatal mortality and brain injury from neonatal encephalopathy. The findings of this trial will be important for low and middle-resource settings where the majority of intrapartum-related events occur. TRIAL REGISTRATION: ClinicalTrials.gov. Identifier: NCT03133572 . Registered April 28, 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Pejovic NJ, Myrnerts Höök S, Byamugisha J, et al. Neonatal resuscitation using a supraglottic airway device for improved mortality and morbidity outcomes in a low-income country: study protocol for a randomized trial. Trials. 2019. PMID: 31324213. doi:10.1186/s13063-019-3455-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。